Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
2
0
0
METACRINE INC
Share · US59101E1038 · MTCR (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of METACRINE INC
Analyst Grade Summary
No Price
Company Profile for METACRINE INC Share
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Company Data
Name METACRINE INC
Company Metacrine, Inc.
Symbol MTCR
Website
https://www.metacrine.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US59101E1038
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO David M. Maggio
Country United States of America
Currency USD
Employees 0,0 T
Address 3985 Sorrento Valley Boulevard, 92121 San Diego
IPO Date 2020-09-16
Dividends from 'METACRINE INC'
| Ex-Date | Dividend per Share |
|---|---|
| 21.06.2023 | 0,58 USD |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | MTCR |
More Shares
Investors who hold METACRINE INC also have the following shares in their portfolio:
